Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658289 | 0.94 | HTR1A (0.58) | HTR1ATP53MAPTKCNH2DRD2 | |
| SCHEMBL5656201 | 0.92 | HTR1A (0.55) | HTR1ATP53MAPTKCNH2DRD2 | |
| SCHEMBL5655859 | 0.91 | GFER (0.55) | HTR1ATP53MAPTDRD4GFER | |
| SCHEMBL5655713 | 0.91 | MEN1 (0.57) | HTR1AMAPTKCNH2DRD4MEN1 | |
| SCHEMBL5656003 | 0.91 | KCNH2 (0.52) | HTR1ATP53MAPTKCNH2DRD2 | |
| SCHEMBL5657422 | 0.89 | HTR1A (0.57) | HTR1AMAPTDRD2GFERMEN1 | |
| SCHEMBL5656027 | 0.87 | TSHR (0.56) | TP53MAPTDRD2HTR2ADRD3 | |
| SCHEMBL5657645 | 0.86 | HTR1A (0.57) | HTR1ATP53MAPTKCNH2DRD2 | |
| SCHEMBL5656794 | 0.85 | HTR1A (0.54) | HTR1AMAPTDRD2DRD4GFER | |
| SCHEMBL5655788 | 0.85 | POLB (0.51) | HTR1AMAPTDRD2DRD4GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | claimed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | HTR1A 8/4885TP53 4247/4885MAPT 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.